NICE was unable to develop medical technologies guidance on the OraQuick® HCV Rapid Antibody Test. Please contact medtech@nice.org.uk for more information. NICE has since developed a Medtech Innovation Briefing (MIB24) on the technology.
 
Status Discontinued
Process MT
Notification date 01 October 2010
Topic area
  • Diagnostic procedures
  • Digestive system
  • Infectious diseases

Provisional Schedule

Topic Selection: 16 December 2010

Email enquiries

Stakeholders

  • If you would like to become a registered stakeholder in the development of guidance on this technology, please complete a stakeholder registration and confidentiality form (Word), and return to us at medtech@nice.org.uk.

    Registered stakeholders will be informed of key stages in the development of guidance including when documents go out to consultation or comment.

Timeline

Key events during the development of the guidance:

Date Update
26 May 2016 Discontinued, NICE was unable to develop medical technologies guidance on the OraQuick® HCV Rapid Antibody Test. Please contact medtech@nice.org.uk for more information. NICE has since developed a Medtech Innovation Briefing (MIB24) on the technology.
5 August 2011 NICE's assessment of this medical technology is suspended.
29 June 2011 NICE is unable to develop medical technology guidance on OraQuick HCV Rapid Antibody Test because the manufacturer has decided not to pursue a submission for evaluation to the Medical Technologies Evaluation Programme (MTEP). NICE will therefore not be developing guidance on this topic.

For further information on how we develop guidance, please see our page about NICE medical technologies guidance